Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.81 |
| ▸ | MMP2 | P08253 | 4/20 | 0.66 |
| ▸ | MMP3 | P08254 | 3/20 | 0.66 |
| ▸ | MMP13 | P45452 | 3/20 | 0.66 |
| ▸ | MMP9 | P14780 | 3/20 | 0.66 |
| ▸ | MMP1 | P03956 | 2/20 | 0.66 |
| ▸ | MMP7 | P09237 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790069 | 1.00 | ADAMTS4 (0.81) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL702793 | 1.00 | ADAMTS4 (0.81) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| Trifluoroacetic Acid SCHEMBL7346536 | 0.90 | ADAMTS4 (0.68) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL4651862 | 0.90 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL1751961 | 0.90 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL17318887 | 0.86 | ADAMTS4 (0.62) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL6798909 | 0.85 | ADAMTS4 (0.70) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL14217417 | 0.85 | MMP9 (0.74) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL698908 | 0.85 | ADAMTS4 (0.71) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL4975578 | 0.85 | ADAMTS4 (0.71) | ADAMTS4MMP2MMP3MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653607-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPBAU E K (DE) | 2023-10-18 | — | — | EP | claimed |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2022-10-18 | — | — | US | claimed |
| EP-3653607-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatenbau e.K. (DE) | 2020-05-20 | — | — | EP | claimed |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2016-09-01 | — | — | US | claimed |
| EP-2958894-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau KG (DE) | 2015-12-30 | — | — | EP | claimed |
| WO-2014128139-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2014-08-28 | — | — | WO | claimed |
| CN-101180029-B | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD | 2011-02-16 | — | — | CN | claimed |
| CN-101180029-A | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD (JP) | 2008-05-14 | — | — | CN | claimed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2024-02-13 | — | — | US | disclosed |
| EP-4289819-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau e.K. (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-3653607-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPBAU E K (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2023-01-12 | — | — | US | disclosed |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2022-10-18 | — | — | US | disclosed |
| EP-0602028-B1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO WEDROPHARM GMBH (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0602028-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | PHARNO WEDROPHARM GMBH (DE) | 1994-06-22 | — | — | EP | disclosed |
| WO-1993005014-A1 | AROMATIC SULFONAMIDE DERIVATIVES, THEIR USE AS ENZYME INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARNO-WEDROPHARM GMBH (DE) | 1993-03-18 | — | — | WO | disclosed |
| US-4618710-A | Preparation of optically active ketones | THE REGENTS OF THE UNIVERSITY OF CALIF. (US) | 1986-10-21 | — | — | US | disclosed |
| US-4113463-A | BENZENESULFONAMIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1978-09-12 | — | — | US | disclosed |
| US-4070176-A | WITH A BENZENESULFONAMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885 |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885 |
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4764/4885MMP2 4338/4885MMP3 3434/4885 |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4743/4885MMP2 4285/4885MMP3 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.